June 29, 2018
Emerging CAR-T immunotherapies leverage modified versions of patient’s T-cells to target and kill cancer cells. In a new study, researchers at University of California San Diego School of Medicine and University of Minnesota report that similarly modified natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) also…
December 10, 2020
…his cancer. New Personalized Immunotherapy Trial Launched Despite COVID-19 Pandemic First patient to receive individualized TIL therapy undergoes treatment at Moores Cancer Center Since 2016, Bernard Thurman has undergone traditional treatments, experimental therapies and surgeries to counter the cancer within him, but nothing successfully eradicated the disease. Earlier this year,…
September 19, 2016
…opening the possibility to further improving and refining emerging immunotherapies that boost the body’s own abilities to fight diseases ranging from cancer to Alzheimer’s and Crohn’s disease.
June 30, 2016
Using a database of human tumor genomic data, researchers at the University of California San Diego, School of Medicine and Moores Cancer Center discovered that mutation hotspots known as kataegis are a positive marker in breast cancer — patients with kataegis have less invasive tumors and better prognoses. The study,…
October 17, 2019
…the newly established Precision Immunotherapy Clinic. Photo by Yadira Galindo/UC San Diego Health New Precision Immunotherapy Clinic Matches Patients to Latest Cancer Therapies Using a personalized approach, Moores Cancer Center at UC San Diego Health employs genetic profiling to treat patients who have not responded to, or relapsed from, standard…
July 9, 2024
Discover research from UC San Diego showing how stem cell-derived therapy, targeting treatment-resistant liver cancer through genetically modified NK cells, offers promising new avenues for immunotherapy.
November 21, 2022
UC San Diego Alpha Stem Cell Clinic awarded $8M to expand clinical trials of novel stem cell therapies. The CIRM award will advance partnerships between academic and industry experts in San Diego to expedite clinical trials for patients with difficult-to-treat diseases.
August 4, 2016
…in San Diego to receive a new type of immunotherapy, known as CAR T-cell therapy, as part of a Phase I/II clinical trial at Moores Cancer Center at UC San Diego Health.
April 27, 2022
The cowpea mosaic virus has shown great promise as an experimental cancer immunotherapy for treating and preventing recurrence of various cancers. But just how the virus triggers such a potent anti-cancer immune response has remained a mystery. A new study digs deeper and provides answers.
March 24, 2020
Rice University researchers used the Comet supercomputer at SDSC to evaluate their new molecular docking too to help improve cancer immunotherapy outcomes by identifying more effective personalized treatments.
